Lung Cancer | Norton Healthcare

Indication: Lung Cancer

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Sub-indication: Non-Small Cell Lung Cancer

Line of Therapy: Front-line

Drug Study

Principal Investigator: Adam Lye, M.D.
Norton Cancer Institute

Sponsor: Arcus Biosciences, Inc.

Learn more at ClinicalTrials.gov

Email for more information: Lung-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.